US2013344056A1PendingUtilityA1

Keratin biomaterials for treatment of ischemia

50
Assignee: UNIV WAKE FOREST HEALTH SCIENCESPriority: Mar 8, 2010Filed: Aug 27, 2013Published: Dec 26, 2013
Est. expiryMar 8, 2030(~3.6 yrs left)· nominal 20-yr term from priority
Inventors:Mark E. Van DykeThomas L. SmithMichael V. CallahanLuke Burnett
A61P 9/00A61P 9/10A61K 38/166A61K 9/0019A61K 38/015A61K 38/49A61K 38/482A61K 31/727A61K 38/1748A61L 2300/252A61L 15/44A61K 45/06A61P 17/02
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are keratin compositions useful for treating ischemia and/or reperfusion injury, such as that associated with myocardial infarct, ischemic stroke, brain trauma such as traumatic brain injury, hypothermia, chronic wounds, and burns.

Claims

exact text as granted — not AI-modified
1 .- 10 . (canceled) 
     
     
         11 . A composition comprising a keratin and further comprising a thrombolytic. 
     
     
         12 . The composition of  claim 11 , wherein said keratin is selected from the group consisting of:
 α-keratose, γ-keratose, keratin associated proteins (KAP), and combinations thereof.   
     
     
         13 . The composition of  claim 11 , wherein said keratin is a combination of α-keratose and keratin associated proteins (KAP). 
     
     
         14 . The composition of  claim 13 , wherein said α-keratose has an average molecular weight of at least 30 kiloDaltons. 
     
     
         15 . The composition of  claim 11 , wherein said composition comprises from 1 to 10% by weight of said keratin. 
     
     
         16 . The composition of  claim 11 , wherein said keratin is from 3 to 5 percent by weight. 
     
     
         17 . The composition of  claim 11 , wherein said composition is formulated for parenteral administration. 
     
     
         18 . The composition of  claim 11 , wherein said thrombolytic is selected from the group consisting of: streptokinase, urokinase, alteplase, reteplase, and tenecteplase. 
     
     
         19 . A composition comprising a keratin and further comprising an anticoagulant. 
     
     
         20 . The composition of  claim 19 , wherein said keratin is selected from the group consisting of: α-keratose, γ-keratose, keratin associated proteins (KAP), and combinations thereof. 
     
     
         21 . The composition of  claim 19 , wherein said keratin is a combination of α-keratose and keratin associated proteins (KAP). 
     
     
         22 . The composition of  claim 20 , wherein said α-keratose has an average molecular weight of at least 30 kiloDaltons. 
     
     
         23 . The composition of  claim 19 , wherein said composition comprises from 1 to 10% by weight of said keratin. 
     
     
         24 . The composition of  claim 19 , wherein said keratin is from 3 to 5 percent by weight. 
     
     
         25 . The composition of  claim 19 , wherein said composition is formulated for parenteral administration. 
     
     
         26 . The composition of  claim 19 , wherein said anticoagulant comprises heparin.

Join the waitlist — get patent alerts

Track US2013344056A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.